Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.

Slides:



Advertisements
Similar presentations
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Advertisements

Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple.
Highlights of the Day II: SARCOMA “The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting.
Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.
A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.
Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.
Presented By Raymond Huang at 2014 ASCO Annual Meeting
As part of the final PP presentation the following slides need to be included.
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.
Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.
A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.
Genes and Function: The Rewriting of our Textbooks of Pathology Presented By David Hafler at 2014 ASCO Annual Meeting.
Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.
Observation of Blood Cells. Slide 1 1. Draw the slide. 2. Common name of Cells 3. Correct name of cells 4. Characteristic #1 5. Characteristic #2.
Basic Immunology of the Mouse (and Human) Nicholas P. Restifo, MD October 19, 2015.
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
By: Ryan Rodriguez. What is it?  Cervical cancer is when abnormal cells on the cervix grow out of control.
Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.
Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Presented.
Highlights of the Day III Genitourinary (Nonprostate) Cancer Presented By Toni Choueiri at 2014 ASCO Annual Meeting.
Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.
Presented By Michael Overman at 2016 ASCO Annual Meeting
A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients.
When Using DOPPS Slides. DOPPS Slide Use Guidelines.
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.
Presented By Shin Fujita at 2016 ASCO Annual Meeting
Presented By Alan Venook at 2016 ASCO Annual Meeting
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Presented By Sham Mailankody at 2016 ASCO Annual Meeting
Presented By Lorenz Trumper at 2016 ASCO Annual Meeting
Presented By Michael Lee at 2016 ASCO Annual Meeting
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Highlights: Myeloma Oral Session
Presented By Antoni Ribas at 2014 ASCO Annual Meeting
Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Presented By John Bartlett at 2017 ASCO Annual Meeting
Presented By Luca Malorni at 2017 ASCO Annual Meeting
continued on next slide
Presented By Amrita Krishnan at 2016 ASCO Annual Meeting
                                                                                                                                                                                                                                                
continued on next slide
continued on next slide
Impact of efficient and inefficient therapies on CTCs and ctDNA.
Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
A subgroup analysis of a large multicenter study
Presented By Praful Ravi at 2016 ASCO Annual Meeting
Presented By Mathias Rummel at 2016 ASCO Annual Meeting
The Road to Quality Improvement in HER2-Positive Breast Cancer
Presented By Steven Park at 2016 ASCO Annual Meeting
Renal Function and Myeloma Therapeutics
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting
continued on next slide
Presented By Joshua Richter at 2016 ASCO Annual Meeting
Presented By Andrew Evens at 2016 ASCO Annual Meeting
Presence of anti-HPV E6/E7 epitope CD8+ T-cell responses in HPV+ OPSCC tumors. Presence of anti-HPV E6/E7 epitope CD8+ T-cell responses in HPV+ OPSCC tumors.
Trends in survival from metastatic lung cancer in California,
T-cell phenotypes of cells harvested from the peripheral blood of patients undergoing chemotherapy. T-cell phenotypes of cells harvested from the peripheral.
Percentage of peripheral blood samples that demonstrated >5-fold in vitro expansion. Percentage of peripheral blood samples that demonstrated >5-fold in.
continued on next slide
MDSC population in patient peripheral blood.
Presentation transcript:

Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting

Metastatic Cervical Cancer Presented By Christian Hinrichs at 2014 ASCO Annual Meeting

Adoptive T Cell Therapy Presented By Christian Hinrichs at 2014 ASCO Annual Meeting

Slide 4 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting

Patient Characteristics Presented By Christian Hinrichs at 2014 ASCO Annual Meeting

Prolonged Tumor Regression Following a Single Infusion of Cells Presented By Christian Hinrichs at 2014 ASCO Annual Meeting

Patient 3 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting

Patient 6 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting

HPV reactivity of the infusion product Presented By Christian Hinrichs at 2014 ASCO Annual Meeting

Patient 3 – Repopulation of Peripheral Blood with HPV reactive T cells Presented By Christian Hinrichs at 2014 ASCO Annual Meeting

Patient 6 – Repopulation of Peripheral Blood with HPV reactive T cells Presented By Christian Hinrichs at 2014 ASCO Annual Meeting

Slide 12 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting

Limitations of the Study Presented By Christian Hinrichs at 2014 ASCO Annual Meeting

Summary of the Findings Presented By Christian Hinrichs at 2014 ASCO Annual Meeting

Conclusions of the Study Presented By Christian Hinrichs at 2014 ASCO Annual Meeting

Acknowledgements Presented By Christian Hinrichs at 2014 ASCO Annual Meeting